Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 1 examiners • 0 of 3 (0%) have an AI response strategy ready
Lonza Houston Inc. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. All 3 of these actions are handled by 1 distinct examiner and are located within 1 distinct art unit. The busiest examiner for the portfolio is ALAM, DANYAL HASSAN, who is managing 3 busiest examiner pending actions. The data reveals an absolute concentration of the workload, as all 3 pending office actions are handled by a single examiner.
This means that the entirety of the company's current prosecution efforts in the Biotechnology & Pharmaceuticals sector are subject to the review of 1 individual, ALAM, DANYAL HASSAN. With only 1 distinct art unit involved, the portfolio's technical scope is highly focused. For practitioners, this indicates that the outcomes for all of the company's pending matters are entirely dependent on the specific examination style and technical interpretation of ALAM, DANYAL HASSAN. This centralized structure simplifies administrative management but places significant reliance on a single point of contact within the patent office for all active cases.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALAM, DANYAL HASSAN | 3 | 66.7% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18480841 | METHODS FOR CHARACTERIZING LENTIVIRUSES | ALAM, DANYAL HASSAN | 23d overdue |
| 18700957 | METHODS FOR PROCESSING AND ANALYZING VIRUS CAPSID PROTEINS | ALAM, DANYAL HASSAN | — |
| 17997266 | METHODS AND KITS FOR DETECTING ADENO-ASSOCIATED VIRUSES | ALAM, DANYAL HASSAN | — |
| Art Unit | Apps |
|---|---|
| 1672 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18700957 | METHODS FOR PROCESSING AND ANALYZING VIRUS CAPSID PROTEINS | ALAM, DANYAL HASSAN | — | §103§112 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18480841 | METHODS FOR CHARACTERIZING LENTIVIRUSES | ALAM, DANYAL HASSAN | 1672 | §103§112 | Final Rejection | 23d overdue | Pending | Oct 04, 2023 |
| 17997266 | METHODS AND KITS FOR DETECTING ADENO-ASSOCIATED VIRUSES | ALAM, DANYAL HASSAN | 1672 | §103§112 | Non-Final OA | — | Pending | Oct 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial